© 2020 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2020 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
November 25, 2020
Roman Perez-Soler, MD, discusses how MET mutations have evolved and impacted the treatment of patients with lung cancer.
November 24, 2020
Matthew Davids, MD, MMSc, discusses the prognosis expected for patients with mantle cell lymphoma, as well as chronic lymphocytic leukemia, in the relapsed/refractory population.
November 21, 2020
John O. Mascarenhas, MD, discusses pacritinib for patients with myelofibrosis and thrombocytopenia.
November 20, 2020
Ryan C. DeCoste, MD, discusses how comprehensive genomic profiling can be used to identify rare subsets of patients with Merkel cell carcinoma.
Petros Grivas, MD, PhD, discusses the phase 3 KEYNOTE-045 trial and the association between gene expression signatures and pembrolizumab in patients with advanced urothelial cancer.
November 19, 2020
Victor Velculescu, MD, PhD, discusses the key takeaways regarding the use of liquid biopsy to detect cancer and a new cfDNA approach to detect cancer at earlier stages.
Maria E. Cabanillas, MD, discusses the pooled results of 2 larotrectinib trials for patients with advanced or metastatic TRK fusion-positive thyroid cancer.
November 18, 2020
Nilanjan Ghosh, MD, discusses the effect coronavirus disease 2019 had on using chimeric antigen receptor T-cell therapy to treat patients with diffuse large B-cell lymphoma.
November 17, 2020
Hope Rugo, MD, discusses her key takeaways in the field of HER2-positive breast cancer.
November 16, 2020
Brain A. Jonas, MD, discusses the future of treatment for older patients with acute myeloid leukemia, now that the FDA has granted approval to azacitidine plus venetoclax for patients aged 75 years or older.